Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi‐institutional case‐control study

Jurczyszyn, Artur; Nahi, Hareth; Avivi, Irit; Gozzetti, Alessandro; Niesvizky, Rubén; Yadlapati, Sujitha; Jayabalan, David; Robak, Paweł; Pika, Tomáš; Andersen, Kristian Thidemann; Rasche, Leo; Mądry, Krzysztof; Woszczyk, Dariusz; Raźny, Małgorzata; Usnarska−Zubkiewicz, Lidia; Knopińska‐Posłuszny, Wanda; Wojciechowska, Małgorzata; Guzicka-Kazimierczak, Renata; Joks, Monika; Grosicki, Sebastian; Ciepłuch, Hanna; Rymko, Marcin; Castillo, Jorge J.

doi:10.1111/bjh.14328

Cited by 31 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only 35% of the patients are younger than 65 years at the moment of diagnosis. Individuals under 40 years of age count for up to 2% of all cases [2]. The annual incidence in Poland in 2017 was approximately 8/100 000/year [3].…”

Section: Incidence and Epidemiologymentioning

confidence: 99%

Multiple myeloma – 2020 update on diagnosis and management

Charliński¹,

Jurczyszyn

2020

Nowotwory. Journal of Oncology

Self Cite

View full text Add to dashboard Cite

There has been remarkable progress made in the diagnosis and treatment of multiple myeloma (MM). The median survival of the disease has doubled as a result of several new active drugs. These advances have necessitated a revision of the disease definition and staging of MM. Until recently, MM was defined by the presence of end-organ damage, specifically hypercalcemia, renal failure, anaemia, and bone lesions (CRAB features) that can be attributed to the clonal process. In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for MM to add three specific biomarkers that can be used to diagnose the disease in patients who did not have CRAB features: clonal bone marrow plasma cells greater than or equal to 60%, serum free light chain (FLC) ratio greater than or equal to 100 provided involved FLC level is 100 mg/l or higher, or more than one focal lesion on MRI. In addition, the definition was revised to allow CT and PET-CT to diagnose MM bone disease. With the introduction of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), major improvements have been achieved in the treatment and outcome of MM. Different treatment combinations are now in use and newer therapies are being developed. However, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of the relapsed disease remains a critical aspect of MM care and an important area of ongoing research. The aim of this review is to summarise the current methods of diagnosis and treatment of MM.

show abstract

Section: Incidence and Epidemiologymentioning

confidence: 99%

Multiple myeloma – 2020 update on diagnosis and management

Charliński¹,

Jurczyszyn

2020

Nowotwory. Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…r.ż.) z grupą 916 chorych w wieku 41-60 lat [17]. Badanie miało charakter retrospektywny i wieloośrodkowy, objęto nim pacjentów leczonych w latach 2000-2015.…”

Section: Szpiczak Plazmocytowy U Osób Młodychunclassified

“…Wyższa skuteczność stosowanej terapii może mieć związek z szerszym wykorzystaniem procedury ASCT u młodszych chorych (Ryc. 6A i B) [17]. osłabienie).…”

Section: Szpiczak Plazmocytowy U Osób Młodychunclassified

Nietypowe objawy kliniczne szpiczaka plazmocytowego

Jurczyszyn

Olszewska-Szopa

2017

Acta Haematologica Polonica

Self Cite

View full text Add to dashboard Cite

Szpiczak plazmocytowy (MM), z częstością występowania w Europie 4,5-6/100000/rok, stanowi 10% nowotworów układu krwiotwórczego. Ta często rozpoznawana choroba limfo-proliferacyjna dotyczy przede wszystkim osób starszych. Średni wiek w chwili zachorowania wynosi 72 lata [1]. Zwykle MM lokalizuje się w szpiku kostnym. Jednakże u 7% pacjentów stwierdza się jego pozaszpikowe nacieki już w chwili rozpoznania, a u kolejnych 6% w dalszym przebiegu choroby [2]. a c t a h a e m a t o l o g i c a p o l o n i c a 4 8 ( 2 0 1 7 ) 1 8 9 -1 9 4 i n f o r m a c j e o a r t y k u l e Historia artykułu:

show abstract

“…Multiple myeloma (MM) is the second most common haematological malignancy, accounting for 1% of all cancers [1]. Induction chemotherapy with novel anti-myeloma agents followed by high-dose melphalan autologous stem cell transplantation (ASCT) remains the gold standard of therapy for younger patients with MM and has led to significantly increased progression-free and overall survival [2].…”

Section: Introductionmentioning

confidence: 99%

Risk of relapse of multiple myeloma following kidney transplantation

Shah

Ibrahim

Delaney

et al. 2019

Clinical Kidney Journal

View full text Add to dashboard Cite

Background Autologous stem cell transplantation (ASCT) and novel therapies have improved the prognosis for patients with multiple myeloma (MM). For those who undergo ASCT while on dialysis, a similar survival compared with the overall MM population has been reported. Therefore, for patients achieving remission following ASCT, kidney transplantation is an attractive option, offering an improved quality of life and significant economic advantage. Method This case series investigates the outcome of five patients who underwent an ASCT for MM with subsequent kidney transplantation between 2006 and 2012. Results Four patients presented with end-stage renal disease (ESRD) and one progressed to ESRD shortly after diagnosis. Induction chemotherapy regimens with novel agents including thalidomide and bortezomib were utilized. Following attainment of very good partial remission or complete remission, high-dose melphalan ASCTs were performed after a median of 10 months. Kidney transplantation (living donor n = 3, deceased donor n = 2) with tacrolimus-based immunosuppression regimens was completed at a median of 27 months after ASCT. Patients 1 and 3 experienced relapse of myeloma at 6 and 16 months after kidney transplantation. Patients 2, 4 and 5 remain alive at 55 months (median) after kidney transplantation with no evidence of relapse. Conclusion Forty percent of our cohort experienced a relapse in MM within 2 years of kidney transplantation. Death-censored graft survival and patient survival were 80% at 4 years. Our study adds to the growing literature supporting kidney transplantation following successful ASCT for MM and is useful when counselling patients regarding renal and haematological outcomes.

show abstract

Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi‐institutional case‐control study

Cited by 31 publications

References 16 publications

Multiple myeloma – 2020 update on diagnosis and management

Multiple myeloma – 2020 update on diagnosis and management

Nietypowe objawy kliniczne szpiczaka plazmocytowego

Risk of relapse of multiple myeloma following kidney transplantation

Contact Info

Product

Resources

About